CHFR‑mediated epithelial‑to‑mesenchymal transition promotes metastasis in human breast cancer cells

Jiang,Guobin; Fang,Hongyan; Shang,Xi; Chen,Xiaopin; Cao,Feilin

doi:10.3892/mmr.2021.12090

CHFR‑mediated epithelial‑to‑mesenchymal transition promotes metastasis in human breast cancer cells

Authors:
- Guobin Jiang
- Hongyan Fang
- Xi Shang
- Xiaopin Chen
- Feilin Cao
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Luqiao, Zhejiang 318050, P.R. China
Published online on: April 15, 2021 https://doi.org/10.3892/mmr.2021.12090
Article Number: 451

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Checkpoint with FHA and RING finger domains (CHFR) is a G₂ phase/mitosis checkpoint. Several studies have reported that CHFR is downregulated in multiple cancer types and serves a tumor suppressor role. However, the biological function of CHFR in breast cancer (BRCA), particularly regarding metastasis, are yet to be elucidated. In the present study, it was revealed that CHFR is upregulated in BRCA compared with normal tissues, according to The Cancer Genome Atlas database. In addition, subgroup analysis of BRCA revealed that CHFR was upregulated in both human epidermal growth factor receptor 2‑positive and triple‑negative BRCA. Meanwhile, patients with high expression levels of CHFR exhibited poorer overall survival rates. Furthermore, the present data revealed that the overexpression of CHFR in SKBR3 cells resulted in enhanced cell migration and invasiveness, and also significantly upregulated mesenchymal markers, such as N‑cadherin, vimentin, transcription factor Slug and tight junction protein claudin‑1. Furthermore, knockdown of CHFR in MDA‑MB‑231 cells significantly inhibited cell migration and invasiveness, and also downregulated mesenchymal markers, such as N‑cadherin, vimentin and tight junction protein claudin‑1. In conclusion, the current results indicated that CHFR expression was associated with cell metastasis in BRCA by mediating epithelial‑to‑mesenchymal transition.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Al-Bahlani S, Al-Lawati H, Al-Adawi M, Al-Abri N, Al-Dhahli B and Al-Adawi K: Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. Apoptosis. 22:865–876. 2017. View Article : Google Scholar : PubMed/NCBI
4	Scolnick DM and Halazonetis TD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 406:430–435. 2000. View Article : Google Scholar : PubMed/NCBI
5	Ding Y, Lian HF and Du Y: Clinicopathological significance of CHFR promoter methylation in gastric cancer: A meta-analysis. Oncotarget. 9:10083–10090. 2018. View Article : Google Scholar : PubMed/NCBI
6	Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y and Takahashi T: Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene. 21:2328–2333. 2002. View Article : Google Scholar : PubMed/NCBI
7	Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, et al: Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 23:1695–1699. 2002. View Article : Google Scholar : PubMed/NCBI
8	Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
9	Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, Ikeda K, Kojima A, Egashira A, Morita M, Kakeji Y and Maehara Y: Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Breast Cancer Res Treat. 97:199–203. 2006. View Article : Google Scholar : PubMed/NCBI
10	Vanharanta S and Massague J: Origins of metastatic traits. Cancer Cell. 24:410–421. 2013. View Article : Google Scholar : PubMed/NCBI
11	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
12	Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zheng H, Shen M, Zha YL, Li W, Wei Y, Blanco MA, Ren G, Zhou T, Storz P, Wang HY and Kang Y: PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell. 26:358–373. 2014. View Article : Google Scholar : PubMed/NCBI
14	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
15	Kashima L, Idogawa M, Mita H, Shitashige M, Yamada T, Ogi K, Suzuki H, Toyota M, Ariga H, Sasaki Y and Tokino T: CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. J Biol Chem. 287:12975–12984. 2012. View Article : Google Scholar : PubMed/NCBI
16	Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG and van Engeland M: Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 33:161–171. 2014.PubMed/NCBI
17	Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS and Ogino S: CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol. 21:245–255. 2008. View Article : Google Scholar : PubMed/NCBI
18	Soutto M, Peng D, Razvi M, Ruemmele P, Hartmann A, Roessner A, Schneider-Stock R and El-Rifai W: Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer. 116:4033–4042. 2010. View Article : Google Scholar : PubMed/NCBI
19	Pillai RN, Brodie SA, Sica GL, Shaojin Y, Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, et al: CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin Cancer Res. 19:1603–1611. 2013. View Article : Google Scholar : PubMed/NCBI
20	Gao L, Liu F, Zhang H, Sun J and Ma Y: CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome. Genes Chromosomes Cancer. 55:158–168. 2016. View Article : Google Scholar : PubMed/NCBI
21	He MY, Rancoule C, Rehailia-Blanchard A, Espenel S, Trone JC, Bernichon E, Guillaume E, Vallard A and Magné N: Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies. Crit Rev Oncol Hematol. 131:96–101. 2018. View Article : Google Scholar : PubMed/NCBI
22	Khaled N and Bidet Y: New insights into the implication of epigenetic alterations in the EMT of triple negative breast cancer. Cancers (Basel). 11:5592019. View Article : Google Scholar : PubMed/NCBI
23	Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, et al: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 8:157732017. View Article : Google Scholar : PubMed/NCBI
24	Nieto MA, Huang RY, Jackson RA and Thiery JP: Emt: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
25	Hinz S and LaBarge MA: Hijacking EMT: Better fat than dead. Cancer Cell. 35:1–2. 2019. View Article : Google Scholar : PubMed/NCBI
26	Yang S, He F, Dai M, Pan J, Wang J and Ye B: CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner. OncoTargets Ther. 12:1075–1084. 2019. View Article : Google Scholar : PubMed/NCBI
27	Privette LM, González ME, Ding L, Kleer CG and Petty EM: Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: Implications for tumor suppression. Cancer Res. 13:6064–6074. 2007. View Article : Google Scholar : PubMed/NCBI